Cardiol Therapeutics | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Cardiol Therapeutics

BRIEF

published on 10/23/2025 at 12:56, 1 month 12 days ago

Cardiol Therapeutics Secures Funding with USD 11.4 Million Private Placement

Private Placement Clinical Trials Financial Outlook Cardiol Therapeutics Heart-Failure Therapy
PRESS RELEASE

published on 10/23/2025 at 12:51, 1 month 12 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates Cardiol Therapeutics Inc with a BUY rating and USD 8.50 price target. The private placement secures funds for pivotal trials and new product development

Private Placement Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating USD 8.50 Price Target
BRIEF

published on 08/12/2025 at 13:36, 3 months 23 days ago

Cardiol Therapeutics: Phase II Trial Results and Positive Stock Outlook

BUY Rating Cardiol Therapeutics CardiolRx Phase II ARCHER Trial Acute Myocarditis
PRESS RELEASE

published on 08/12/2025 at 13:31, 3 months 23 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc after positive phase II trial results for CardiolRx in acute myocarditis

Cardiol Therapeutics Inc First Berlin Equity Research Phase II Trial CardiolRx Acute Myocarditis
BRIEF

published on 04/23/2025 at 15:29, 7 months 11 days ago

Cardiol Therapeutics Advances in Pivotal Phase III Study

FDA Approval Cardiol Therapeutics Phase III Study Recurrent Pericarditis CardiolRxT
PRESS RELEASE

published on 04/23/2025 at 15:24, 7 months 11 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation for Cardiol Therapeutics Inc, maintaining Buy rating and USD 8.50 target price. CardiolRxT phase III study enrollment for recurrent pericarditis (RP) shows promise for FDA approval

FDA Approval Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating CardiolRxT
BRIEF

published on 11/22/2024 at 11:11, 1 year ago

Cardiol Therapeutics Secures Buy Rating Amid Promising Trial Results

Clinical Trials BUY Rating Cardiol Therapeutics CardiolRx Drug Efficacy
PRESS RELEASE

published on 11/22/2024 at 11:06, 1 year ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Cardiol Therapeutics Inc. with USD8.50 price target based on positive final data for CardiolRx in treating recurrent pericarditis

Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating Reaffirmed CardiolRx
BRIEF

published on 10/28/2024 at 15:51, 1 year 1 month ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
PRESS RELEASE

published on 10/28/2024 at 15:46, 1 year 1 month ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 56 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 1 minute ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 16 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE